Simultaneous use of rapidly absorbed and sustained release theophylline preparations in children. 1979

E W Hein, and J F Domson, and A Sheen, and G J Buffone, and R M Sly

Each of 12 asthmatic children received a single dose of Theolair, 5 mg/kg, a single dose of Theolair SR, 10 mg/Kg, or both Theolair, 3 mg/Kg and Theolair SR, 10 mg/Kg on three separate days. Administration of both preparations together was followed by serum theophylline concentrations significantly higher than Theolair alone at 2 or 12 hours and significantly higher than Theolair SR alone at every time except six hours. This method of theophylline administration may be useful in the asthmatic patient who requires medication only intermittently.

UI MeSH Term Description Entries
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000042 Absorption The physical or physiological processes by which substances, tissue, cells, etc. take up or take in other substances or energy.
D001249 Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL). Asthma, Bronchial,Bronchial Asthma,Asthmas
D013806 Theophylline A methyl xanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Theophylline inhibits the 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE that degrades CYCLIC AMP thus potentiates the actions of agents that act through ADENYLYL CYCLASES and cyclic AMP. 1,3-Dimethylxanthine,3,7-Dihydro-1,3-dimethyl-1H-purine-2,6-dione,Accurbron,Aerobin,Aerolate,Afonilum Retard,Aquaphyllin,Armophylline,Bronchoparat,Bronkodyl,Constant-T,Elixophyllin,Euphylong,Glycine Theophyllinate,Lodrane,Monospan,Nuelin,Nuelin S.A.,Quibron T-SR,Slo-Phyllin,Somophyllin-T,Sustaire,Synophylate,Theo Von Ct,Theo-24,Theo-Dur,Theobid,Theocin,Theoconfin Continuous,Theodur,Theolair,Theolix,Theon,Theonite,Theopek,Theophylline Anhydrous,Theophylline Sodium Glycinate,Theospan,Theostat,Theovent,Uniphyl,Uniphyllin,Uniphylline,1,3 Dimethylxanthine,Anhydrous, Theophylline,Constant T,ConstantT,Ct, Theo Von,Glycinate, Theophylline Sodium,Quibron T SR,Quibron TSR,Slo Phyllin,SloPhyllin,Sodium Glycinate, Theophylline,Somophyllin T,SomophyllinT,Theo 24,Theo Dur,Theo24,Theophyllinate, Glycine,Von Ct, Theo
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

E W Hein, and J F Domson, and A Sheen, and G J Buffone, and R M Sly
February 1990, The Journal of allergy and clinical immunology,
E W Hein, and J F Domson, and A Sheen, and G J Buffone, and R M Sly
May 1985, Drug and therapeutics bulletin,
E W Hein, and J F Domson, and A Sheen, and G J Buffone, and R M Sly
March 1984, Harefuah,
E W Hein, and J F Domson, and A Sheen, and G J Buffone, and R M Sly
January 1988, Journal de pharmacie de Belgique,
E W Hein, and J F Domson, and A Sheen, and G J Buffone, and R M Sly
January 1984, British journal of clinical practice. Supplement,
E W Hein, and J F Domson, and A Sheen, and G J Buffone, and R M Sly
January 1992, Journal of pharmaceutical and biomedical analysis,
E W Hein, and J F Domson, and A Sheen, and G J Buffone, and R M Sly
January 1992, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
E W Hein, and J F Domson, and A Sheen, and G J Buffone, and R M Sly
May 1998, Arzneimittel-Forschung,
E W Hein, and J F Domson, and A Sheen, and G J Buffone, and R M Sly
January 1983, Arzneimittel-Forschung,
E W Hein, and J F Domson, and A Sheen, and G J Buffone, and R M Sly
May 1983, American journal of diseases of children (1960),
Copied contents to your clipboard!